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Abstract: Catalysts are employed in many areas of research and development where they combine
high efficiency with often astonishing selectivity for their respective substrates. In biology, biocatalysts
are omnipresent. Enzymes facilitate highly controlled, sophisticated cellular processes, such as
metabolic conversions, sensing and signalling, and are prominent targets in drug development.
In contrast, the therapeutic use of catalysts per se is still rather limited. Recent research has shown
that small molecule catalytic agents able to modulate the redox state of the target cell bear considerable
promise, particularly in the context of inflammatory and infectious diseases, stroke, ageing and even
cancer. Rather than being “active” on their own in a more traditional sense, such agents develop their
activity by initiating, promoting, enhancing or redirecting reactions between biomolecules already
present in the cell, and their activity therefore depends critically on the predisposition of the target
cell itself. Redox catalysts, for instance, preferably target cells with a distinct sensitivity towards
changes in an already disturbed redox balance and/or increased levels of reactive oxygen species.
Indeed, certain transition metal, chalcogen and quinone agents may activate an antioxidant response
in normal cells whilst at the same time triggering apoptosis in cancer cells with a different pre-existing
“biochemical redox signature” and closer to the internal redox threshold. In pharmacy, catalysts
therefore stand out as promising lead structures, as sensor/effector agents which are highly effective,
fairly selective, active in catalytic, i.e., often nanomolar concentrations and also very flexible in their
structural design.
Keywords: catalysis; cellular thiolstat; drug design; enzymes; mimics; redox modulation; selenium;
sensor/effector agents; transition metal complexes
1. Introduction
Catalysts take centre stage in many scientific disciplines and processes, from large scale industrial
manufacture of substances such as ammonia to the common exhaust of petrol-powered automobiles
where platinum catalysts detoxify some of the toxic by-products of fuel combustion. According to
Barack Obama, even civil society is “a catalyst for change”, yet chemistry employs a narrower definition
of catalysis and catalysts involved [1,2]. Here, catalysts are agents which essentially promote the
conversion of certain substrate(s) to product(s) by taking part in the reaction without being consumed
or produced. Notably, the catalyst acts on the kinetics, not on the thermodynamics of the reaction.
This means that: (a) its actions rely critically on the presence of suitable substrates and (b) catalysts
may seemingly initiate, promote, enhance or even redirect energetically favourable reactions, yet are
unable to trigger energetically unfavourable reactions. This aspect of catalysis is often overlooked and
the cartoon in Figure 1 tries to emphasize this “catalytic principle”. In other words, although catalysts
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cannot perform thermodynamic miracles, they may speed up reactions which otherwise would be
so slow that one may actually assume that they cannot occur at all. In addition, the catalyst is highly
selective for the presence of suitable substrates and is limited in the range of products it is able to
produce. Indeed, nothing happens if the catalyst is left devoid of its substrates.
Figure 1. Cartoon illustrating the “catalytic principle” in the context of cellular processes. Inside
cells various reactions are unfavourable kinetically and therefore possible yet slow (A). A suitable
catalyst can accelerate such reactions significantly by “tunnelling through” the activation energy hill (B).
It should be noted that this “catalytic tunnel” is not open to all kind of substrates, hence catalysts
also provide a degree of selectivity (in this case for H2O2). Besides such direct catalytic interferences
with cellular targets, certain catalysts are also able to deplete the cell of essential components, such
as GSH or NAD(P)H or convert certain cellular components into natural or even unnatural, cytotoxic
substances which react more rapidly with their cellular targets (C). A special and particularly attractive
case is the interconversion of ROS (D).
Translated into biology terms, this simple notion of catalysis turns into the quintessence of
cellular function, which is facilitated and controlled tightly by enzymes. It also provides an amazing
spectrum of possibilities for intervention and, eventually, pharmaceutical drug design (Figure 2).
Indeed, biology is an El Dorado for catalysis, where enzymes and other catalytic molecules, such as
catalytic pieces of RNA, drive and control virtually all biochemical processes, from energy metabolism
Molecules 2018, 23, 765 3 of 22
and cell cycle progression to redox signalling and apoptosis [3–14]. Enzymes are located intracellularly
(i.e., in the cell membrane, cytosol, nucleus, mitochondria) or extracellularly and act in extremely small
quantities. Such enzymatic action can exert a pronounced influence of the cell as enzymes are able
to “process” hundreds or thousands of substrate molecules per second and some of them, such as
superoxide dismutase (SOD), operate almost at the limit of diffusion with a catalytic rate constant of
1 × 10−10 M−1 s−1 estimated for human CuZnSOD and O2 − at physiological pH [15].
Figure 2. Enzymes take centre stage in innovative drug design, often as targets for inhibitors. See text
for details.
Hardly surprising, pharmaceutical research for decades has considered enzymes, including
human, bacterial, viral, fungal, and protozoal protein kinases, proteases, esterases, phosphatases and
ATPases, as potential targets (Figure 2). Drugs containing enzyme inhibitors are legend, such as
penicillins which inhibit a specific transpeptidase and serve as broad-spectrum antibiotics [16].
Such inhibitors are also prominent in other fields, for instance as antiviral drugs, where zidovudine
and lamivudine inhibit nucleotide reverse transcriptase and serve in the treatment of human
immunodeficiency virus (HIV), and in cancer research, where one only needs to consider
methotrexate, which inhibits tetrahydrofolate dehydrogenase and hence impairs DNA synthesis and
cell proliferation [17–19]. Along these very lines, a recent review by Stefania Schiavone and colleagues
describes the role of various small molecule catalysts in neuropsychiatric and neurodegenerative
disorders [20].
It is therefore startling that traditional drug design and development has consistently shied away
from the wider therapeutic application of catalysts. Still, there are notable and highly instructive
exemptions, examples of biological and chemical catalysts—in a wider sense—already employed or
under development. As part of this review, and as prelude to the Special Issue on “Small molecule
catalysts with therapeutic potential”, we will briefly consider some of these highlights with the aim to
foster a wider understanding of their enormous potential and potential future applications.
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2. The Use of Enzymes in Therapy
If one were to unleash the power of biocatalysis in therapy, the most obvious choice would
probably involve the application of enzymes per se, as they are, literally, the natural choice of catalysts,
being omnipresent in biological systems and evolved to highly efficient and at the same time selective
macromolecules with impressive catalytic turnover rates and an amazing specificity for just one or a
few substrates. Indeed, at closer inspection one finds some rather prominent examples of enzymes used
already directly in therapy, often even by oral administration. A concise selection of these examples is
mentioned in Figure 2.
The gastrointestinal tract, for instance, is a prime target for enzyme therapy, from a serious
pancreatic enzyme replacement therapy for nutrient malabsorption (lipase, amylase, and protease)
and pancreatic insufficiency to rather trivial yet notorious Beano® anti-gas remedies based on the
Aspergillus niger enzyme α-galactosidase [21–23]. Equally melodically and important are thrombolytic
and fibrinolytic “clot-busting” agents which rely on a class of enzymes, originally streptokinase and
urokinase [24]. These enzymes convert plasminogen to plasmin, which subsequently solubilizes fibrin
and therefore degrades a blood thrombus and embolus. Even in the field of anticancer drugs, enzymes
play some role. Asparaginase, a bacterial hydrolytic enzyme is used as an antineoplastic agent in
humans as part of the chemotherapy regimen of acute lymphoblastic leukaemia (ALL), acute myeloid
leukaemia (AML) and non-Hodgkin’s lymphoma [25–27]. Its mode of action is surprisingly simple
yet effective. It hydrolyses asparagine to aspartic acid and hence deprives proliferating cells of this
essential amino acid [25,28,29].
Another proteolytic group of enzymes relevant in human medicine is known as Bromelain, which
actually stands for a mixture of cysteine proteases obtained from the stems, leaves and fruits of
pineapple (Ananas comosus), and represents the active ingredient of a herbal remedy taken orally to
treat oedema and chronic rhinosinusitis [30–32].
There are quite a few additional examples of enzymes serving as active ingredients—or even as
preservatives—in medications and similar preparations. Still, the idea of using such macromolecules
as drugs is somewhat daring, not because of lack of activity but due to an inherent, very poor
pharmacokinetic profile. As for most proteins, oral availability is limited—although there are claims
that enzymes such as the proteases of the Bromelian cocktail can be found in the bloodstream [32].
Unpleasant injections, usually intravenous, intramuscular or subcutaneous, remain the most common
route for administering such therapeutics. Besides their poor oral bioavailability, enzymes are also
prone to degradation, their transport into cells is complicated and, eventually, if injected, they may
trigger a severe immune response, such as an extreme allergic reaction resulting in anaphylactic
shock [33].
To circumvent such complications and issues with externally administered enzymes, different
avenues have been explored, ranging from gene therapy to produce “therapeutic” enzymes at
their desired destination and an induced (over-)expression of certain enzymes, to complicated
antibody-enzyme hybrid systems and eventually small molecule enzyme mimics (Figure 2).
Gene therapy, which aims at the lifetime replacement of a defective gene with a corrected version,
probably represents the most obvious but also revolutionary of these approaches. Strategies such as
engineering SOD in cells under oxidative stress are quite convincing, and gene delivery of members of
the SOD family, particularly manganese superoxide dismutase (MnSOD), and of catalase, are known
as “radio-protective gene therapy” [34]. Today, clinical trials to test the safety and effectiveness of gene
therapy for haemophilia A and B are ongoing [35]. Nonetheless, the successful implementation of
gene therapy is extremely complicated in practice since it requires sophisticated delivery systems [36].
Vectors used to shuttle the corrected versions of the genes usually include plasmids, retroviruses,
adenoviruses, and the adeno-associated virus (AAV) [37,38]. Even if a safe and effective gene therapy
based on well-established vectors may spare the patients the agony of frequent enzyme drug injections,
neutralizing antibodies, not only against the “healthy enzyme” but also against the—often viral—vector
have been reported, further complicating this approach [39].
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Less invasive alternatives are considering the controlled overexpression of enzymes from already
existing genes. In fact, certain studies have demonstrated the prospect to increase the expression of
enzymes by external stimulus, similar to the “induction” of protein expression in the liver or in bacterial
cultures with the notorious isopropyl β-D-1-thiogalactopyranoside [40]. Glutathione peroxidase and
thioredoxin reductase activity in the body can be increased, for instance, via an increased intake of
dietary selenium [41–43]. Compared to gene therapy, this avenue towards increased amounts and
activities of certain enzymes appears to be rather simple and mild, and is interesting, especially in
the context of chemoprevention, food supplementation and quality of life in the elderly. Nonetheless,
such primitive nutritional approaches are limited in scope. Concentrations of the relevant enzymes
cannot be increased by large margins, the method is neither specific for just one desired enzyme or
location, and in any case is limited to a handful of known examples. It is also somewhat difficult
to control in practice, with over-supplementation of substances such as selenium representing a
tangible risk.
Another alternative to the direct application of isolated enzymes involves prior modification to
reduce the risk of being recognized as a target by the immune system. Eloquent enzyme-antibody
hybrids, for instance, are not only able to “mask” an alien enzyme to prevent the immune response,
but also to target the enzyme towards specific organs or cells. Here, cells interacting with the antibody
of the hybrid via specific receptors appear to be affected preferably by this antibody targeted therapy,
as has been demonstrated for the enzyme alliinase, which converts its harmless alliin substrate to the
aggressive thiosulfinate allicin [44]. In a pioneering study by Rabinkov and colleagues, the intra-venous
application of such an alliinase-antibody hybrid prior to the administration of alliin substrate via
various routes, including orally, successfully targeted an ovarian carcinoma in a mouse model
in vivo [45]. It appears that once injected into the bloodstream, the enzyme-antibody hybrid swiftly
located at the preferred site of action and that the cytotoxic allicin was formed primarily at this site.
Since allicin itself is not particularly stable chemically, similar studies have considered a combination
of alliinase and synthetic alliin substrates as a cytotoxic “binary agent”, with possible applications
in medicine and agriculture [46]. Related therapeutic “binary weapons” based on an enzyme and
substrate combination include the enzyme myrosinase found in mustard and rapeseeds and its
various glucosinolate substrates, which together form a spectrum of highly aggressive isothiocyanates,
thiocyanates, nitriles and thiosulfinates [32,47,48].
Intriguingly, allicin by itself appears to be catalytic and since its discovery in 1944 by Cavallito
and Bailey, has been studied extensively because of its pronounced cytotoxic activity [49,50]. As part
of this Special Issue Slusarenko and his colleagues once more emphasize this unusual activity, whereby
allicin is not only active against Pseudomonas aeruginosa, Streptococcus pyogenes, Streptococcus agalactiae,
Streptococcus dysgalactiae, Streptococcus pneumonia or Staphylococcus aureus when added as liquid,
but—astonishingly—even as a vapour [51]. From a pharmacological perspective, allicin may therefore
bear some promise against lung pathogens, for instance via inhalation. In addition to “binary systems”,
antimicrobial applications via the gas phase seem particularly attractive, as they avoid the kind of
barriers faced along the oral route. As a sigh of relief, allicin and its decomposition products are
usually “safe” for humans, as they are also formed within the human body from orally ingested garlic,
and are even occasionally suspected of being active as bactericidal agents in the airways via the unique
route of exhalation [51,52].
3. From Enzyme Mimics to Artificial Catalysts
Allicin serves as fragrant prelude to a wider range of natural and synthetic small molecule
catalysts. Since most protein-based therapies, despite the various efforts described above, are still
difficult to develop and to implement, chemists over the years have rather successfully explored
“mimics” for a wide range of such enzymes, which primarily imitate their activity, yet avoid the
“protein ballast” and complications which come with them. In essence, mimics retain certain pivotal
features of the enzymes they are inspired by, for instance active site elements such as selenium, metal
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ions, functional groups or specific intermolecular interactions deemed important for activity and/or
selectivity. Still, they differ otherwise dramatically from their parent enzymes, most obviously in size
and chemical composition, but also in properties such as—metabolic—stability, polarity, solubility and
bioavailability, all of which are important for possible therapeutic applications. It is a challenge for
subsequent “generations” of mimics to “inch closer” to their respective parent enzymes, not only by
higher catalytic turnover numbers but also by more predictable substrate profiles and other refinements
which are often motivated by key features found in the parent enzyme and its active site. At the same
time, synthetic chemistry is well equipped to deviate from the natural protein blueprint and to add
specific design features, such an improved chemical stability and solubility, resilience against proteases
and, eventually, desirable pharmacokinetic features along the “Lipinski in the Oral Office” catchphrase
of 1990s drug design [53,54].
Glancing over the vast number of catalytically active mimics of different enzymes produced over
the years, it is hardly surprising that some of them have also been considered as potential drugs,
and redox modulating catalysts are no exception. Stimulated by the many transition metal based redox
enzymes, numerous complexes of copper, iron, manganese, ruthenium, iridium and other transition
metals have been designed, synthesized and evaluated extensively for biological activity. For instance,
various mimics of the copper, zinc- and the manganese-containing superoxide dismutases, SOD1,
SOD2 and SOD3, respectively, have been investigated as possible therapeutic antioxidants. Here,
metalloporphyrin-based SOD mimics are the most widely known, yet other structures, such as Mn
cyclic polyamines, Mn salen derivatives or even non-metal based molecules, among them water-soluble
fullerenes, have proven their efficiency as good SOD-like catalysts [55,56]. Similarly, the family of
antioxidant selenium-containing glutathione peroxidase (GPx) enzymes has given rise to a vast number
of structurally highly diverse mimics which are generally based on selenium or tellurium and over the
years have been considered as therapeutic antioxidants, but increasingly also as selective inducers of
apoptosis (see Figure 2 and below) [57].
As in the case of SOD mimics, the chemistry at the active site of the parent enzyme may be seen
as a guide but not as a must. Mugesh and his colleagues have recently described isonanoenzymes
with a pronounced GPx-like activity and able to regulate the concentration of H2O2, yet based on
V2O5, i.e., on a redox active element and material which differs entirely from the chalcogen-based
small molecules traditionally considered in the context of GPx activity [58]. The fact that mimics—as
small molecule catalysts—are considerably more flexible when compared to enzymes, and may also be
incorporated into larger molecules, such as proteins and even nanomaterials, will be revisited later on.
Returning to catalysis and selenium, the compound ebselen (2-phenyl-1,2-benzoselenazol-3-one)
has gained its prominence thanks to its catalytic activity and good pharmacological profile and ranks
first among the very few selenium compounds which so far have entered clinical trials, in its specific
case to prevent some of the damage caused by ischemic stroke and to treat symptoms of hypomania
and mania in bipolar patients [59,60]. Although potential medical applications of ebselen are still
debatable, this compound can be considered as a pioneer in the field of catalytic redox drugs.
Mimicking enzymes is therefore promising, but perhaps also narrows down a wider view on
catalysis. Indeed, the desire to “inch closer” to the activity and substrate specificity of the parent
enzyme, which for instance has long dominated the field of GPx mimic design, eclipses the rather
interesting circumstance that more indiscriminate catalysts may actually open up new avenues.
In the field of cytotoxic catalytic agents, where undesired or even alien reactions are employed
to compromise the target cell, such a “badly behaved”, indiscriminate behaviour of the catalyst
paradoxically may hold the key to selective therapeutic activity. Certain tellurium compounds support
this notion. Originally developed as antioxidants, these agents have turned out to be more of a
“loose redox catalytic cannon” in a cellular environment, and hence are able to target certain cells
when employed in sub-micromolar concentrations [61,62]. In Group 16, the isosteric replacement
along the line of sulphur—selenium—tellurium tends to enhance activity, and numerous tellurium
compounds have been considered as potential antioxidants, not only in the context of human health
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and disease, but also for the preservation of materials and foodstuffs, as the research into radical-chain
breaking agents by Engman and colleagues illustrates nicely [63,64]. Concurrently, moving from
selenium to tellurium also diminishes any meaningful selectivity for GSH and turns the catalyst
somewhat—but not entirely—indiscriminate against protein thiols (PrSH) (see Section 4). The resulting
catalytic onslaught on the “cellular thiolstat”—a concept introduced to resolve the apparent paradox
between indiscriminate chemical reactivity and pharmaceutical selectivity (see Section 4)—disrupts
the intracellular redox homeostasis and hence renders many of these tellurium compounds outright
toxic for certain types of cells [65]. Indeed, “loose cannon” redox catalysts with a certain selectivity
for cells with an already disturbed redox signature have attracted quite some interest, not only in
the context of GPx and chalcogens, but also in other quarters, which have, independently provided
support for this simple yet elegant catalytic solution to efficiency and selectivity.
Within the realm of pharmacy some of the most striking recent examples of synthetic catalytic
agents able to enter and impair living cells by an undesired and de facto detrimental catalysis involve
organometallic compounds. Here, the Sadler group has been at the forefront of designing and
developing transition metal-based catalysts able to perform unusual types of catalysis, often alien and
damaging to certain types of cells (see Figure 1 for the catalytic principle and Figure 3 for relevant
chemical structures). Playing virtuously and vigorously on the keyboard provided by the d-block
elements in the Periodic Table, this group over the years has developed organoruthenium(II) as
well as organoiridium(III) agents which catalyse various redox reactions, not only in vitro but also
inside living cells. Some of the reactions facilitated involve the photochemical formation of singlet
oxygen (1O2) by organoiridium(III) complexes in human lung cancer A549 and MRC-5 cells, ROS
generation and depletion of reduced glutathione (GSH) in human ovarian A2780 and lung cancer A549
cells by Ru(II) complexes, as well as an interference with the central cellular NAD(P)H/NA(D)P+ redox
couple in ovarian cancer A2780 cells by Ru(II) catalyzed Noyori-type transfer hydrogenation [66–70].
Very recently, a particularly interesting class of asymmetric transfer hydrogenation catalysts has
emerged in the shape of Os(II) arene sulfonyl diamine complexes, which enter ovarian A2780 cancer
cells where they reduce pyruvate in the presence of a suitable source of formate to either D- or L-lactate,
whereby the stereochemistry of the product depends on the stereochemistry of the Os(II) complex
applied [67–69]. In contrast to most of the previously employed small molecule redox catalysts, such as
iridium, quinones, chalcogens, which act as oxidative stressors, these osmium-based catalysts cause a
specific form of reductive stress. Since their catalytic activity relies on the presence of a suitable formate
substrate, they also show some selectivity for ovarian cancer cells when compared to non-cancerous
ovarian and lung fibroblast cells. One of these osmium complexes is also effective in attacking PC3
prostate cancer cells, albeit in this case rather unselectively, as its substrate N-formylmethionine is
present in target PC3 prostate cancer cells as well as in normal cells [67]. The significance of small
molecule catalysts in various fields is summarized in Figure 4.
There are some lessons to be learned from the biological activity of these and similar small
molecule redox catalysts. To achieve a more selective behaviour, one should avoid the need to
administer both, catalyst and substrate, as this will diminish selectivity. One should also reconsider
depriving cells generally of their fuel, such as NAD(P)H, GSH, or amino acids, such as asparagine
and glutamine, as this will affect the cell in a wider, possibly uncontrolled manner [71]. In contrast,
catalysts which operate with substrates limited to or primarily found in target cells or, alternatively,
catalysts which generate products which are particularly damaging to the target cells, but not to normal
cells, tend to attain higher selectivity. This fine but crucial difference between catalysts which rely
on externally added substrates and eventually may result in “binary systems”, and catalysts which
find and hence also sense the presence of their substrates in certain cell types is illustrated in Table 1.
It should be noted that both types of catalysts have their own attraction, and both have been explored
in the context of drug design, with different outcomes, strengths, drawbacks and potential applications.
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Figure 3. Chemical structures of the most important agents and catalysts discussed. allicin (1),
diallyltetrasulfide (DATTS) (2), embelin (3), quercetin (4), cinnamic acid (5), 7,7′-tellurobis-ß-tocopherol (6),
benzo[c]selenophene-1,3-dione (7), 2,3-bis(phenyltellanyl)naphthalene-1,4-dione (8), 1,2-di-(quinolin-
8-yl)diselane (9), Mn(III)tetrakis(4-benzoic acid)porphyrin (10), (R,R)-[Ru(η6-C6H5(CH2)3Ts
DPEN-N-Me)Cl] (11) and [Os(η6-p-cymene)(4-(2-pyridylazo)-N,N-dimethylaniline)I]PF6 (12).
Figure 4. During the last decade, catalysts have been considered for various preventive and/or
therapeutic purposes. Whilst natural agents with certain catalytic properties are de facto employed
already as nutraceuticals in the field of nutrition or as nutrageceuticals (nutraceuticals employed to
maintain or restore health and quality of life during ageing), other small molecule catalysts are still
being developed and tested. Here, sensor/effector agents represent a particularly interesting class of
agents as they fine-tune existing biochemical signatures. See text for details.
Molecules 2018, 23, 765 9 of 22
Table 1. Enzymes and enzyme mimics may both be employed in prevention and therapy and both
provide individual advantages and disadvantages. Hybrid molecules have recently been considered as
a mean to combine such benefits whilst minimizing any drawbacks. See text for details.
Parameters Enzyme (±Substrate) Small Molecule Catalyst(Mimic)
Hybrid of Small Molecule
Catalyst and Protein
Origin Natural Artificial Combination
Molecular weight High (well above 10 to 100 kDa) Low (100–300 Da) High
Stability Sensitive to degradation Generally stable Intermediate
Administration Usually intravenously Oral administration feasible Usually intravenously
Immune response Common if administeredintravenously Rare Possible but avoidable
Selectivity for substrates Highly selective for specificsubstrates May use various substrates May use various substrates
Selectivity for pre-existing
biochemical signatures
Can be selective if substrate
present
Can be selective if substrate
present
Can be selective if substrate
present
Active transport to cellular
targets Usually not selective Not selective
Possible if antibodies are
involved
4. Redox Catalysts with Sensor/Effector Properties
If one were to avoid the addition of extra substrates in combination with the catalyst, then
small molecules able to transform reactive oxygen species (ROS) are a good choice. Firstly, ROS
levels differ considerably between cells, and many target cells, such as microbes, inflammatory cells
and cancer cells are particularly rich in ROS and hence also particularly prone to damage by ROS
processing catalysts [72,73]. In fact, certain ROS can be converted catalytically into others (see also
Figure 1), and inside cells, such conversions may dramatically increase the damaging properties of
ROS, as exemplified by the transformation of hydrogen peroxide (H2O2) to the highly aggressive
hydroxyl radical ( OH). Most of these ROS react with protein thiols as mentioned above.
Secondly, ROS are a fine choice of (pre- or pro-)cytotoxic agents as they tend to damage a wide
range of biomolecules, yet in a controlled manner, which leads to cellular signalling and not simply
to “poisoning”, as in the case of unnatural catalysts and products. Indeed, catalysts generating or
employing ROS operate with “natural” oxidative stressors. Their impact on cells is therefore dramatic,
yet paradoxically also controlled—often proceeding via distinctive signalling pathways and ending
in programmed cell death, i.e., apoptosis. This implies that any catalyst promoting such damaging
reactions would not only be highly effective, but also highly selective. It would act exclusively in the
presence of ROS and cause damage via existing cellular pathways and without any major damage to
normal cells or poisoning of the surrounding tissue and organism.
As prelude to this theme, and before considering individual small molecule catalysts in more
detail, one may briefly turn towards the few cases where malfunctioning redox enzymes become
associated with human disorders, as those natural examples highlight the severeness of catalysis gone
badly. A mutated Cu, Zn-SOD in Familial Amyotrophic Lateral Sclerosis (FALS) is such an enzyme.
FALS manifests itself in 5% of the patients with the motor neuron disease amyotrophic lateral sclerosis
(ALS) [74,75]. From a molecular perspective, the deficient SOD is still active catalytically, yet has lost
some of its specificity and besides converting O2•− to H2O2 and O2 also reduces H2O2 to OH radicals.
These radicals are amongst the most aggressive oxidative stressors and cause considerable damage to
the cells and organs affected in patients suffering from this genetic disorder [76].
Perhaps in part inspired by this kind of “almost but not quite natural” cytotoxic redox
catalysis, compounds such as the manganese complex mangafodipir (2-[2-[carboxylatomethyl-[[5-
[[hydroxy(oxido)phosphoryl]oxymethyl]-2-methyl-3-oxidopyridin-4-yl]methyl]amino]ethyl-[[2-methyl-
3-oxido-5-(phosphonooxymethyl)pyridin-4-yl]methyl]amino] acetate; manganese(2+)) have been
applied successfully by Batteux and his colleagues as radical generators in a range of target cells,
including human leukocytes and murine CT26 colon cancer cells [77,78]. Similar studies have
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confirmed these findings, employing, for instance, the superoxide dismutase mimic GC4419 to transfer
one electron from ascorbate to O2•−, thereby subsequently generating the more aggressive H2O2 and
distorting the intracellular redox balance [79]. Ironically, other SOD mimetics, such as MnDPDP and
calmangafodipin [Ca4Mn(DPDP)5] have been described as selective cyto-protective agents, in essence
acting via an antioxidant mechanism [80].
Whilst belonging to the same family of Mn-complexes, this apparent contrast in activity is due to
the individual redox behaviour of the catalysts, the redox environment they are placed in, the kind
of catalysis they perform, and the competition of simultaneously triggered, yet partially conflicting
signalling pathways (see Section 5). In the case of mangafodipir, it is therefore conceivable that such
agents selectively protect normal tissues from chemotherapy-induced toxicity, whilst they allow or even
enhance damage to tumour tissue(s), for instance as part of a combination therapy with oxaliplatin [81].
In fact, a recent report on manganese porphyrins has stressed this dichtometry, whereby the same
compound protects normal prostate cells against radiation damage whilst it inhibits the growth of
prostate cancer cells [82].
By radical generation, and similar to the mutant SOD in FALS, such Mn-complexes do not
interfere with their eventual cellular targets, such as redox-sensitive proteins, directly. These targets
only become damaged once ROS are (trans-)formed and react further, or, in the case of protective
agents, are guarded from oxidation because the relevant ROS are sequestered before they can cause any
widespread damage. GPx mimics, in contrast, react directly and hence are more focussed. Such mimics
primarily employ ROS on the one side and thiols, and occasionally some selenols, on the other, as their
two substrates. This unique combination of sensing—of ROS—with the effects—on thiols—ensures
a maximum of activity and selectivity, even at the molecular level. With this concept of effective yet
selective catalytically active “sensor/effector” agents in mind, a colourful palette of compounds has
been produced since the turn of the Millennium, with hues of pink for simple selenides and diselenides
during early in proof-of-concept phases to considerably more complex structures with added features
and activities, and often featuring the more active tellurium instead of selenium [72,83,84]. Some of
this selenium chemistry has been highlighted in the review by Domínguez-Álvarez and his colleagues
which forms part of this Special Issue.
In 2003, a small series of molecules combining a chalcogen with an additional quinone redox
centre for extra activity has been reported, and the activity of these multifunctional redox modulating
molecules in submicromolar concentrations and in cell lines such PC 12 by far eclipsed the one of
simpler chalcogen-based GPx mimics considered under similar conditions a few years earlier [85,86].
Since then, the idea of multifunctional redox agents with ROS generating as well as ROS utilizing
functionalities has inspired the development of a wider range of extraordinarily catalytic agents with
two or more—mostly catalytic—redox sites brought together in one molecule. These agents have
been evaluated rather successfully against a range of targets, from bacteria and fungi to cancer cells,
macrophages and fibroblasts [87,88]. One particularly intriguing study considered the impact of these
catalysts on chronic lymphoblastic leukaemia (CLL) cells derived from patients suffering from chronic
lymphoblastic leukaemia in comparison to normal blood cells derived from the same, individual
patients [89]. This study revealed a significant, pre-existing difference in levels of ROS between the
cancer and normal cells. It also confirmed the ability of the tellurium catalyst employed to increase
these ROS levels particularly strongly in the CLL cells but not in the normal cells, eventually pushing
the cancer cells over a critical “redox threshold”. As expected, the induction of apoptosis was more
significant in the cancer cells, and much lower in the normal cells, pointing towards a good selectivity
of the catalyst and the underlying catalytic principle.
Since then, this area of redox research has turned into a true El Dorado for synthetic chemists as
well as biologists. From the perspective of chemistry, there are many ways to perfect such biologically
active redox catalysts, from assembling complicated molecules with a well-tuned orchestra of multiple
redox sites to keeping it small and replacing selenium with tellurium or fiddling with the selenium
carburettor until the molecule gathers speed (Figure 5).
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Figure 5. During the last couple of years, various strategies have been explored in order to increase the
catalytic activity and selectivity of redox catalysts. See text for details.
Eloquent coupling methods have been explored, for instance, to assemble multifunctional,
multi-catalytic agents, from classical coupling to Passerini and Ugi multicomponent reactions [90].
Recently, Silva and his colleagues have used click chemistry to access a wide palette of such compounds
combining quinones, including naturally occurring lapachones, with sulfur and selenium redox
centres [91]. These and similar compounds have been evaluated rather successfully against a range
of targets and may bear some promise in the field of antimicrobial, anti-inflammatory, scleroderma,
psoriasis and anticancer research to name a few. Indeed, skin diseases may be a prime target for such
compounds, as the research of Mueller and colleagues has indicated [92–94].
Whilst multi-catalytic agents may be considered as the El Dorado, tellurium is not only the
name of a ghost town in Colorado, but far from being abandoned, also an interesting element to
increase further activity and possibly also selectivity in chalcogen-based redox catalysts attacking
the cellular thiolstat [95]. Within the niche of biological tellurium chemistry, we find quite a few
compounds which act as potent, cell type-specific cytotoxic agents and hence may be employed
against oxidatively stressed cancer cells [62]. Related compounds are rather selectively active against
proliferating fibroblasts in in vitro and in mouse models of systemic sclerosis (scleroderma, SSc) [96].
It should be noted that tellurium, as a semi-metal, also forms some complex-like structures, such as
compound AS101, which in many ways resemble some of the transition metal complexes mentioned
above. Tellurium complexes frequently show some high, albeit not entirely well-behaved biological
activity against target cells, yet with a possible negative impact on neurons [97].
The reactivity of selenium in compounds, for instance in the isoselenazole ebselen, can also be
improved considerably by placing a positive charge at the nitrogen in the selenium-nitrogen bond.
As Arsenyans and his colleagues have shown, the resulting selenazolinium salts are incredibly reactive
and also active against a wide range of cancer cell lines [98]. Similarly, Handzlik and her colleagues,
employing the same palette of selenazolinium salts have demonstrated that such compounds also
act against certain resistant strains of bacteria [59]. Other unusual selenium compounds, for instance
inspired by natural antioxidants, such as resveratrol, may be obtained by isosteric replacement of
the omnipresent oxygen atoms in these natural products. Interestingly, certain selenium derivatives
of resveratrol, i.e., benzo[b]selenophenes, protect the yeast S. cerevisiae from oxidative damage by
decreasing the ROS level down to just 12% when compared to the control whereas resveratrol itself
decreases the ROS level to 50% [99].
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Besides these natural compounds with isosterically introduced selenium, there are many
compounds which per se may be classified as “Reactive Selenium Species” (RSeS), as redox and
biologically active selenium compounds of natural origin [100]. Albeit more limited in abundance
when compared to the related class of “Reactive Sulfur Species” (RSS), these RSeS are also highly
reactive, often catalytic and quite selective for thiols as one preferred cellular reaction partner and
substrate, the other one being ROS. From a bio-catalytic perspective, selenols seem to be particularly
interesting due to their catalytic activity, and whilst free selenols (RSeH) are incredibly sensitive
towards oxidation, they can also be protected easily in form of diselenides or selenoesters. These esters
seem to hydrolyse slowly, and the resulting selenium species appear to be rather reactive and also
active in several biological test systems [101,102]. Recent studies by Sanmartin, Domínguez-Álvarez
and their respective colleagues have confirmed this selenium “prodrug” approach employing esters,
anhydrides and slow hydrolysis as a mean to stabilize and deliver highly active selenium species.
In the future, researchers digging for the ultimate selenium catalysts may also revisit some of the
already known reactive selenides and seleninic acids, including the lode of heterocyclic organic agents
laid bare by Kirsch and his colleagues [103,104]. They may also turn towards small molecule catalysts
attached to proteins, i.e., so-called “catalyst protein conjugates”, to ensure “delivery” or to biologically
active nanoparticles composed entirely of catalytic material or composition of materials [105].
5. Targets for Redox Catalysts: A Selected Many
Traditionally, virtually all studies concerned with the synthesis of redox modulators, pro-
and antioxidants alike, have also reported some information related to the redox activity and
catalytic behaviour of such compounds in vitro, for instance in radical scavenging assays, specific
glutathione peroxidase assays, dye-based redox assays or electrochemical studies [106–110]. Nowadays,
an increasing number of publications also provides evidence in cell culture, ranging from bacteria,
fungi and yeasts to mammalian cells. It is therefore hardly surprising that the question of cellular
targets for these catalysts has emerged, a question which may not simply be answered by in vitro assays
which certainly are instructive yet clearly fall short of the complexity of a living cell or even organism.
In other words, a transition metal complex which may be catalytically active in the 96-multi-well
plate may not exhibit the same activity in a multicellular organism, as it may be unable to enter cells,
may not be stable under those conditions, may be sequestered by certain cellular components or may
be metabolized and eventually kicked out of the back door before being able to exert its activity.
As a consequence, simple in vitro redox assays may be sufficient to demonstrate that certain
antioxidants protect your apple juice from turning brown or—as mentioned in the Section 3—protect
foodstuffs from oxidative degradation. Yet they are inadequate to predict or even explain the activity
of redox catalysts in cells or entire organisms. To illuminate such mechanisms and modes of action,
one needs to investigate living cells and small organisms with methods which enable analysis inside
intact cells. Today, several, often complimentary approaches and techniques are available for this
purpose, which include various proteomic methods, chemogenetic phenotype profiling, cell sorting and
extensive process-selective fluorescent staining techniques known as “intracellular diagnostics” [87].
Redox proteomics has developed considerably during the last decade, from early “hunts” for
posttranslational modifications in proteins to an extensive “mining” using eloquent and often expensive
tools. These hunter-gatherer and miner studies have eventually surfaced a number of potential targets
for redox modulation, among them many cysteine residues in proteins and enzymes, and have
given rise to new concepts such as the “sulfenome” and the “redoxome” [111,112]. Compared to
redox genomics, proteomics and metabolomics, chemogenetic phenotype profiling is perhaps not that
well known [113]. It essentially screens single-mutant libraries, usually of Saccharomyces cerevisiae,
for increased or decreased sensitivity towards a given agent and subsequently tries to associate the
proteins affected by the mutation to the agent and its mode(s) of action. In contrast, to proteomics,
which considers changes inside single cells in a more holistic manner and chemogenetic phenotype
profiling, which in parallel looks at tens, hundreds or even thousands of mutants, “intracellular
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diagnostics” considers individual changes in individual cells employing specific fluorescent staining
and visualization techniques. Importantly, such analysis can provide quantitative information crudely
averaged over a range of cells using a fluorescent plate reader, quantitative information on the level of
single cells using fluorescent assisted cell sorting (FACS) and even qualitative insights into cellular
processes at different cellular locations within single cells using fluorescent microscopy. Amazingly,
modern instruments are equipped with different lasers and it is therefore even possible to illuminate
simultaneously several different cellular components and processes in the same sample or cell using
different stains with distinct excitation and emission wavelengths. This approach relies heavily on
the availability of selective stains, and since the turn of the Millennium, a wide spectrum of selective
fluorescent stains has become available. Today, it is possible, for instance, to stain for—quantitative
changes to—intracellular levels of various metal ions, ROS, singlet oxygen (1O2), the superoxide
radical anion (O2 −), thiol levels, the mitochondrial membrane potential, caspase activity and phases
of apoptosis, to name just a few.
During the last decade, such methods have been employed increasingly to decipher the mode(s)
of action associated with many redox modulating and catalytic agents, including various selenols,
selenides, seleninic acids and organotellurium compounds [62,88,96,114,115]. These studies have
consistently revealed a considerable redox imbalance in typical target cells, such as macrophages,
bacteria, plasmodia, yeasts and cancer cells. This pre-existing disturbance singles out the target from
the healthy cells and, as may be expected, is usually potentiated by the redox catalysts, with a loss
of cellular thiols and an increase in levels of ROS. Such changes do not go unnoticed by the cell,
and whilst some cells, such as retinal endothelial ARPE 19 cells, eventually mount an antioxidant
response via factors such as Nrf2, other cells, such as human cancer HCT 116 cells, under the same
conditions enter into apoptosis [116–118]. Interestingly, “intracellular diagnostics” has also revealed
some striking differences between the action of redox catalysts on the one side and traditional cytotoxic
agents and inducers on the other. First of all, the catalysts are not selective for just one protein,
for instance, one particular receptor or enzyme, and hence differ from the kind of classic inhibitors
mentioned in the Introduction. Similar to the cytotoxic transition metal complexes discussed in
Section 3, such quinone and chalcogen-based catalysts are rather indiscriminate and simultaneously
target numerous proteins as their perceived substrate(s), usually but not always particularly redox
sensitive cysteine proteins with cysteine accessible for modification, such as β-tubulin [119]. Yet in clear
contrast to the noble metal catalysts developed by Sadler and colleagues at Warwick, chalcogen-based
catalysts do not simply deplete the cell of its fuel or GSH, or poison the cell with ROS or unnatural
products. Such catalysts operate rather via the oxidation of thiol and selenol proteins, and as such
trigger well established cellular response cascades which eventually lead to a recovery or apoptosis.
This rather unusual specificity for certain cysteine proteins under certain conditions of pre-existing
oxidative stress eventually explains, at least in part, the considerable yet selective activity observed in
certain target cells, such as plasmodia, bacteria, macrophages, cancer cells and even for uncontrolled
proliferating fibroblasts in a mouse model of SSc [96,120].
As a biological twist, such studies have also revealed that not all cysteine peptides, proteins
and enzymes are equally prone to oxidation, as one may have anticipated naïvely along the lines of
“cysteine being cysteine”. GSH, for instance, has long been thought to protect protein thiols from
oxidation because of its sheer abundance, often reaching millimolar concentrations in the cytosol.
Yet GSH is surprisingly sluggish in its reactivity and some proteins, such as β-tubulin, and also certain
enzymes, despite their comparably low abundance, seem to become oxidatively modified even in
the presence of a large excess of GSH. This surprising sensitivity is probably due to a combination of
thermodynamic and kinetic factors, such as electrochemical redox potential, exposure on the surface,
cellular compartmental location and the kinetics of the reaction. Indeed, it seems that only a limited
number of cysteine proteins respond initially or extensively to an oxidative onslaught, and in a
measured and largely reversible manner. Even a more substantial external redox attack often proceeds
in a rather well-defined manner. Cellular proteins, rather than the catalyst itself, provide a certain
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selectivity here, of target and also of response, a finding which has given rise to the concept of the
“cellular thiolstat” [65]. The “cellular thiolstat” brings together the most reactive, yet otherwise diverse
cysteine proteins and enzymes as the prime targets for redox modulation, sensing, response and
signalling, thereby providing a rationale for the action of redox modulating and catalytic agents.
It should be mentioned that the concept of the “cellular thiolstat” is constantly developing. These days,
additional proteins are being identified as being modified by different redox active agents and able to
convey cellular signals, and these signals are also being studied in more detail.
6. Conclusions and Future Perspectives
The previous sections have highlighted some of the rather unique features of catalytic agents in
drug development, from the unique combination of high efficiency and selectivity of therapeutically
administered enzymes to the ability of small molecule catalysts to initiate, promote, enhance or
even redirect energetically favourable reactions. Certain drawbacks, such as poor bioavailability,
chemical and metabolic instability and shocking immune responses against therapeutic proteins have
also been mentioned and no doubt complicate the development and applications of such molecules.
Still, the success of very different catalysts, which range from osmium complexes catalysing transfer
hydrogenation, lactate formation from formate and reductive stress on one side to organotellurium
compounds facilitating an oxidative onslaught on redox sensitive proteins of the “cellular thiolstat”
in the presence of elevated levels of ROS on the other, demonstrates that the catalytic principle is
not simply an idée fixe limited to one or two exotic compounds. In fact, redox-active small molecule
catalysts—and among them mimics of specific redox enzymes such as SOD and GPx in particular—act
in low concentrations and with considerable selectively, depending on the presence of their substrates.
These catalysts are superior to their parent enzymes, as they do not carry any “protein ballast” and are
also more flexible in their design, physico-chemical properties and applications.
Future studies in this field of biological redox catalysis are therefore promising and supported
by the fact that one catalytic selenium compound, namely ebselen, has already reached clinical trials.
Similar RSeS, far from being “alien” to biology, are found increasingly naturally in humans and animals,
one only needs to consider the selenium analogue of ergothioneine, namely selenoneine, which was
recently discovered in the blood of tuna fish [121]. This chemically unusual selenone is probably
only the tip of the iceberg of not yet identified natural RSeS in Biology, including in mammals and
in humans.
Fortunately, the development of such redox catalysts can rely on strong support from analytical
and synthetic chemistry, with an increasing number of researchers worldwide joining the effort to
design, develop and test such catalysts against a wide range of human diseases, from cancer and
infections to inflammation and scleroderma. Ironically, the chemistry of elements such as selenium
and tellurium, iridium and osmium, long confined to niches and of limited interest in biology—where
quite a few students still believe that selenium and osmium are homage on Selena Gomez and Ozzie
Osbourne—is bearing significant promise. A recent renaissance of selenium chemistry with meetings
such as the BioSePe meeting 2016 in Cracow reflects the growing interest in this field, and one may
anticipate similar developments in the years to come. In the future, interest may not only revolve
around traditional catalysts “borrowed” from chemistry and “dumped” into biological systems, such as
the initial generations of manganese and other transition metal complexes, but rather focus on well
selected and designed agents. No doubt, these catalysts will still be inspired by existing knowledge of
chemical catalysis, yet will also adhere to basic principles of biochemistry and drug development.
Within such a multidisciplinary ménage à trois of synthetic chemistry, biochemistry and drug
development, future research may follow several interesting leads. The prospect of assembling
multifunctional redox modulators which perform several tasks, such as ROS generation via a quinone
and catalytic ROS conversion(s) via a selenium or tellurium moiety may be expanded to a more
sophisticated kind of mimics which no longer imitates the function of an individual enzyme, but of an
entire (immune) cell. From the perspective of (cell) biology, the idea of a partially synthetic “immune
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cell mimic” is, of course, a daring, challenging idea, but also one with considerable promise. From the
perspective of chemistry, all one can say is “yes, we can”, as combinations of quinones, chalcogens
and transition metal ions, perhaps even in macromolecules or in nanoparticles, are not out of reach.
Indeed, whilst a simple selenium substitution in a given flavonoid such as quercetin adds a scent of
redox catalysis, implementing such a change in an oligomeric, tannin-like proanthocyanidin results
in a macromolecule with massive redox firing power based on multiple quinone and chalcogen
redox centres. Similarly, artificial proteins rich in selenocysteine residues, possibly stabilized by
complexing redox active metal ions, or polymeric selenides, seleninic acids or selenocysteine, would
also be of considerable interest. At the same time, one may envisage small molecule catalysts
attached to carrier proteins, similar to the alliinase-antibody hybrids [105]. Or why not go “solid” by
considering catalytic nanomaterials, such as synthetic or even natural nanoparticles of sulfur, selenium
or tellurium? [122–125].
No doubt, synthetic chemistry will be at the forefront of this research, it will have to provide the
means to “assemble” the various required features in comparably small molecule catalysts amenable
for potential pharmaceutical applications. Mode of action studies, which will have to accompany
any activity screens, will provide further evidence as to which cells are particularly sensitive to redox
regulation and how exactly they are affected by redox modulation. At the same time, most of the
compounds discussed here have not yet been investigated thoroughly for their toxicity, medium and
long-term side effects and metabolic transformation in more complex organisms. Here, bioavailability
will become an issue, as some of the agents employed so far are only poorly soluble and may need to
be nanosized and stabilized as part of the NaLyRe sequence in order to be applied [122]. Whilst data
already available in some mammals appears promising, clinical trials in this field so far have almost
solely focussed on the SOD mimic manganofodipir and the GPx mimic ebselen.
Irrespective of such “hopes, aspirations and telephone numbers”—to quote Bert L. Vallee—and one
may add “concerns”, the features of catalysis, which are deeply rooted in biology, are extraordinarily
attractive and impossible to ignore in the field of drug design. With many human, animal and plant
diseases on the rise and new and innovative agents desperately required, why not give the large and
small molecule catalysts a genuine chance?
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Chovanec, M. Resveratrol-inspired benzo[b]selenophenes act as anti-oxidants in yeast. Molecules 2018, 23.
[CrossRef] [PubMed]
100. Jawad Nasim, M.; Ali, W.; Dominguez-Alvarez, E.; da Silva Junior, E.N.; Saleem, R.S.Z.; Jacob, C. Chapter
10 reactive selenium species: Redox modulation, antioxidant, antimicrobial and anticancer activities.
In Organoselenium Compounds in Biology and Medicine: Synthesis, Biological and Therapeutic Treatments; The Royal
Society of Chemistry: London, UK, 2018; pp. 277–302.
101. Dominguez-Alvarez, E.; Gajdacs, M.; Spengler, G.; Palop, J.A.; Marc, M.A.; Kiec-Kononowicz, K.; Amaral, L.;
Molnar, J.; Jacob, C.; Handzlik, J.; et al. Identification of selenocompounds with promising properties to
reverse cancer multidrug resistance. Bioorg. Med. Chem. Lett. 2016, 26, 2821–2824. [CrossRef] [PubMed]
102. Dominguez-Alvarez, E.; Plano, D.; Font, M.; Calvo, A.; Prior, C.; Jacob, C.; Palop, J.A.; Sanmartin, C. Synthesis
and antiproliferative activity of novel selenoester derivatives. Eur. J. Med. Chem. 2014, 73, 153–166. [CrossRef]
[PubMed]
103. Prim, D.; Joseph, D.; Kirsch, G. Synthesis of new 2,5-diaryl selenophenes. Phosphorus Sulfur Silicon Relat. Elem.
1994, 91, 137–143. [CrossRef]
104. Kirsch, G.; Cagniant, P.; Cagniant, D.; Backes, C. The aryl acetic acids new synthons for 3-aryl heterocyclic
sulfur coumpounds and their analogs in the selenium and tellurium series. Phosphorus Sulfur Silicon
Relat. Elem. 1979, 6, 161. [CrossRef]
Molecules 2018, 23, 765 21 of 22
105. Pariagh, S.; Tasker, K.M.; Fry, F.H.; Holme, A.L.; Collins, C.A.; Okarter, N.; Gutowski, N.; Jacob, C.
Asymmetric organotellurides as potent antioxidants and building blocks of protein conjugates. Org. Biomol.
Chem. 2005, 3, 975–980. [PubMed]
106. Viswanathan, U.M.; Burkholz, T.; Jacob, C. Electrochemistry at the edge of reason: Chalcogen-based redox
systems in biochemistry and drug design. Z. Phys. Chem. 2013, 227, 691–706. [CrossRef]
107. Ozyurek, M.; Bektasoglu, B.; Guclu, K.; Apak, R. Hydroxyl radical scavenging assay of phenolics and
flavonoids with a modified cupric reducing antioxidant capacity (CUPRAC) method using catalase for
hydrogen peroxide degradation. Anal. Chim. Acta 2008, 616, 196–206. [CrossRef] [PubMed]
108. Flohe, L.; Gunzler, W.A. Assays of glutathione-peroxidase. Methods Enzymol. 1984, 105, 114–121. [PubMed]
109. Lee, S.; Park, Y.; Kim, J.; Han, S.J. A fluorescence-based assay for measuring the redox potential of
5-lipoxygenase inhibitors. PLoS ONE 2014, 9. [CrossRef] [PubMed]
110. Jiang, J.Z.; Bian, Y.Z.; Furuya, F.; Liu, W.; Choi, M.T.M.; Kobayashi, N.; Li, H.W.; Yang, Q.C.; Mak, T.C.W.;
Ng, D.K.P. Synthesis, structure, spectroscopic properties, and electrochemistry of rare earth sandwich
compounds with mixed 2,3-naphthalocyaninato and octaethylporphyrinato ligands. Chem. Eur. J. 2001, 7,
5059–5069. [CrossRef]
111. Waszczak, C.; Akter, S.; Eeckhout, D.; Persiau, G.; Wahni, K.; Bodra, N.; Van Molle, I.; De Smet, B.;
Vertommen, D.; Gevaert, K.; et al. Sulfenome mining in arabidopsis thaliana. Proc. Natl. Acad. Sci. USA 2014,
111, 11545–11550. [CrossRef] [PubMed]
112. Thamsen, M.; Jakob, U. The redoxome proteomic analysis of cellular redox networks. Curr. Opin. Chem. Biol.
2011, 15, 113–119. [CrossRef] [PubMed]
113. Warringer, J.; Anevski, D.; Liu, B.; Blomberg, A. Chemogenetic fingerprinting by analysis of cellular growth
dynamics. BMC Chem. Biol. 2008, 8. [CrossRef] [PubMed]
114. Schneider, T.; Muthukumar, Y.; Hinkelmann, B.; Franke, R.; Doring, M.; Jacob, C.; Sasse, F. Deciphering
intracellular targets of organochalcogen based redox catalysts. Med. Chem. Commun. 2012, 3, 784–787.
[CrossRef]
115. Doering, M.; Diesel, B.; Gruhlke, M.C.H.; Viswanathan, U.M.; Manikova, D.; Chovanec, M.; Burkholz, T.;
Slusarenko, A.J.; Kiemer, A.K.; Jacob, C. Selenium- and tellurium-containing redox modulators with distinct
activity against macrophages: Possible implications for the treatment of inflammatory diseases. Tetrahedron
2012, 68, 10577–10585. [CrossRef]
116. Allah, D.R.; Schwind, L.; Abu Asali, I.; Nasim, J.; Jacob, C.; Gotz, C.; Montenarh, M. A scent of therapy:
Synthetic polysulfanes with improved physico-chemical properties induce apoptosis in human cancer cells.
Int. J. Oncol. 2015, 47, 991–1000. [CrossRef] [PubMed]
117. Saidu, N.E.B.; Touma, R.; Abu Asali, I.; Jacob, C.; Montenarh, M. Diallyl tetrasulfane activates both the eiF2
alpha and Nrf2/HO-1 pathways. Biochim. Biophys. Acta 2013, 1830, 2214–2225. [CrossRef] [PubMed]
118. Saidu, N.E.B.; Abu Asali, I.; Czepukojc, B.; Seitz, B.; Jacob, C.; Montenarh, M. Comparison between the
effects of diallyl tetrasulfide on human retina pigment epithelial cells (ARPE-19) and HCT116 cells. Biochim.
Biophys. Acta 2013, 1830, 5267–5276. [CrossRef] [PubMed]
119. Yagdi Efe, E.; Mazumder, A.; Lee, J.Y.; Gaigneaux, A.; Radogna, F.; Nasim, M.J.; Christov, C.; Jacob, C.;
Kim, K.W.; Dicato, M.; et al. Tubulin-binding anticancer polysulfides induce cell death via mitotic arrest and
autophagic interference in colorectal cancer. Cancer Lett. 2017, 410, 139–157. [CrossRef] [PubMed]
120. Marut, W.; Jamier, V.; Kavian, N.; Servettaz, A.; Winyard, P.G.; Eggleton, P.; Anwar, A.; Nicco, C.; Jacob, C.;
Chereau, C.; et al. The natural organosulfur compound dipropyltetrasulfide prevents HOCl-induced
systemic sclerosis in the mouse. Arthritis Res. Ther. 2013, 15. [CrossRef] [PubMed]
121. Yamashita, Y.; Yabu, T.; Yamashita, M. Discovery of the strong antioxidant selenoneine in tuna and selenium
redox metabolism. World J. Boil. Chem. 2010, 1, 144–150. [CrossRef] [PubMed]
122. Griffin, S.; Sarfraz, M.; Hartmann, S.F.; Pinnapireddy, S.R.; Nasim, M.J.; Bakowsky, U.; Keck, C.M.;
Jacob, C. Resuspendable powders of lyophilized chalcogen particles with activity against microorganisms.
Antioxidants 2018, 7. [CrossRef] [PubMed]
123. Estevam, E.C.; Griffin, S.; Nasim, M.J.; Denezhkin, P.; Schneider, R.; Lilischkis, R.; Dominguez-Alvarez, E.;
Witek, K.; Latacz, G.; Keck, C.; et al. Natural selenium particles from Staphylococcus carnosus: Hazards or
particles with particular promise? J. Hazard. Mater. 2017, 324, 22–30. [CrossRef] [PubMed]
Molecules 2018, 23, 765 22 of 22
124. Faulstich, L.; Griffin, S.; Nasim, M.J.; Masood, M.I.; Ali, W.; Alhamound, S.; Omran, Y.; Kim, H.; Kharma, A.;
Schafer, K.H.; et al. Nature’s hat-trick: Can we use sulfur springs as ecological source for materials with
agricultural and medical applications? Int. Biodeterior. Biodegrad. 2017, 119, 678–686. [CrossRef]
125. Schneider, T.; Baldauf, A.; Ba, L.A.; Jamier, V.; Khairan, K.; Sarakbi, M.B.; Reum, N.; Schneider, M.; Roseler, A.;
Becker, K.; et al. Selective antimicrobial activity associated with sulfur nanoparticles. J. Biomed. Nanotechnol.
2011, 7, 395–405. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
